Archives — February 2017 back to current month (9)
Major Funds Betting On Trump Sector (02/25/2017)
Donald Trump's presidency is a real nitro boost for the future of the biotech sector in the U.S., says Tom Beck, editor of Portfolio Wealth Global.
Buckle Up: Inflation at 58-Month High (02/23/2017)
The stage has been set for high levels of uncertainly, and with uncertainty comes opportunities in commodities, posits Lior Gantz, editor of Wealth Research Group, who also sees opportunities in disruptive technologies in the medical arena.
As Viveve Medical ramped up its U.S. sales force, reported record earnings, increased the number of countries that have given regulatory approval and saw the results of its VIVEVE I clinical study published in the Journal of Sexual Medicine, a trio of analysts took notice.
Stocks in all areas of life sciences including biotech to pharma have been on a roller coaster since Donald Trump won the election in November. Wealth advisor Kristin McFarland discusses the big picture for pharmaceutical investment under the new administration.
Regeneus, an Australian regenerative medicine company, has entered into a collaboration with a major Japanese firm to manufacture its stem cell therapy Progenza, a move that may accelerate approval and that has a pair of analysts optimistic about the company's future.
Luminor Drives the Scout DS Forward (02/06/2017)
Veteran investor Bob Moriarty discusses Luminor Medical Technologies, whose Scout DS technology offers a noninvasive diabetic screen, measuring blood-sugar levels without taking blood.
The Future of Cannabis Investing (02/03/2017)
The cannabis industry attained new highs in 2016, paving the way for some big changes this year, says Tom Beck, senior editor of Portfolio Wealth Global.
ContraVir's Hep B Drug Could Be a Game Changer (02/01/2017)
In light of a Q4/16 announcement by ContraVir Pharmaceuticals about the effectiveness of its compound targeting the hepatitis B virus (HBV), several analysts believe expanding its Phase 2a dose escalation trial could lead to positive results for a population that represents an unmet medical need, as well as for the company.
Companies Flocking to Japan for Biotech Deals (02/01/2017)
For the last two years, Japan has been at the forefront of accelerated approval for regenerative medicine products and has seen lots of licensing and contract manufacturing deals and M&A activity. Tokyo-based Colin Lee Novick, managing director of CJ PARTNERS, surveys the landscape, discussing recent tie-ups, the effects of the recently passed 21st Century Cures Act in the U.S., and what may lie ahead.
|"We are initiating coverage on PMN."|
|"We continue to view DRRX as undervalued and reiterate our Buy rating."|
|"SPR's acquisition in the pipeline creates water-soluble cannabis."|